Zinc Therapy in HIV Infected Individuals Who Abuse Drugs
NCT ID: NCT00149552
Last Updated: 2012-03-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
231 participants
INTERVENTIONAL
2001-06-30
2007-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Zinc Effect on Inflammation and Cardiovascular Risk in HIV
NCT05085834
Zinc Supplementation and Cardiovascular Risk in HIV
NCT02856269
Researching Alveolar Macrophage Improvements With Supplements in HIV
NCT02264860
The Effects of Anti-HIV Drugs on the HIV Virus in HIV-Infected Patients
NCT00006442
Statin Therapy to Improve Atherosclerosis in HIV Patients
NCT00965185
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This trial will last 30 months. Participants will be randomly assigned to receive either zinc supplements or placebo. Male participants will receive 15 mg of zinc and female participants will receive 12 mg of zinc. Clinical and laboratory study visits will occur at 3 or 6 month intervals throughout the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Zinc gluconate
Zinc supplementation
zinc
supplementation with zinc gluconate
Placebo
Placebo
zinc
supplementation with zinc gluconate
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
zinc
supplementation with zinc gluconate
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Drug User
* Blood zinc level greater than 0.35 mcg/mL and less than 0.75mcg/ml
Exclusion Criteria
* Blood selenium level less than 85 mcg/L
* Pregnant or intends to become pregnant
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
Florida International University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marianna Baum
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marianna K. Baum, PhD
Role: PRINCIPAL_INVESTIGATOR
Florida International University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Camillus House
Miami, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Baum MK, Lai S, Sales S, Page JB, Campa A. Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV-infected adults. Clin Infect Dis. 2010 Jun 15;50(12):1653-60. doi: 10.1086/652864.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIDA-14966-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.